Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease

Chest

Volumn 110, Issue 4, 1996, Pages 889-895

  McCoy, Karen ^a   Hamilton, Scott ^b   Johnson, Charles ^b  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b GENENTECH INC   (United States)

Author keywords

cystic fibrosis; dornase alfa; pulmonary exacerbation; pulmonary function; recombinant human DNase

Indexed keywords

ANTIBIOTIC AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; DORNASE ALFA; PLACEBO;

ADOLESCENT; ADULT; AEROSOL; ARTICLE; CHILD; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LENGTH OF STAY; LUNG FIBROSIS; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRACHEOBRONCHIAL TOILET; TREATMENT OUTCOME;

EID: 0029921953     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.110.4.889     Document Type: Article

References (17)

1. Patient Registry 1993 Annual Data Report. Bethesda, Md; Cystic Fibrosis Foundation; 1994
2. Kereni E, Reisman J, Corey M, et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992; 326:1187-91
3. Hodson ME, Madden BP, Steven MH, et al. Noninvasive mechanical ventilation for cystic fibrosis patients: a potential bridge to transplantation. Eur Respir J 1991; 4:524-27
4. Bauldoff GS, Nunley DR, Manzetti JD, et al. Predictors of survival in cystic fibrosis before and after lung transplantation. Am J Respir Crit Care Med 1995; 151:A81
5. Shak S, Capon DJ, Hellmiss R, et al. Recombinant human DNase reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990; 87:9188-92.
6. Rubin BK, Ramirez OE, Baharav AL, et al. The physical and transport properties of CF sputum alter treatment with rhDNase [abstract]. Pediatr Pulmonol 1993; 9(suppl):A251
7. Tomkiewicz RP, Shak S, King M. Effects of rhDNase on cystic fibrosis sputum viscoelasticity in vitro [abstract]. Pediatr Pumonol 1993; 9(suppl):A251
8. Zahm JM, Girod de Bentzmann S, Deneuville E, et al. Dose-dependent effect of recombinant human DNase on the transport properties of cystic fibrosis respiratory mucus [abstract]. Am Rev Respir Dis 1994; 149:A671
9. Shall PL, Ingham S, Marriott C, et al. The in vitro effects of two novel drugs on the rheology of cystic fibrosis and bronchiectasis sputum. Eur Respir J 1994; 7(suppl 18):12S
10. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994; 331:637-12
11. Shah PI, Bush A, Canny GJ, et al. Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by 6 months open-label treatment. Eur Respir J 1995; 8:954-58
12. The Cystic Fibrosis Foundation Center Committee and Guidelines Subcommittee. The Cystic Fibrosis Foundation guidelines for patient services, evaluation, and monitoring in cystic fibrosis centers. Am J Dis Child 1990; 144:1311-12
13. Knudson RJ, Lebowitz MD, Holberg CJ, et al. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983; 127:725-34
14. Gift AG. Validation of a vertical visual analogue scale as a measure of clinical dyspnea. Rehabil Nurs 1989; 14:323-25
15. American Thoracic Society. Standardization of spirometry: 1987 update. Am Rev Respir Dis 1987; 136:1285-98
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-81
17. Cox DR. Regression models and life tables. J R Stat Soc (B) 1972; 34:187-220